AstraZeneca PLC partners with Modella AI for AI-driven drug development

AstraZeneca PLC (AZN) partners with Modella AI to accelerate AI-driven clinical development in oncology. The strategic partnership grants AstraZeneca access to Modella AI’s foundation models for data extraction, aiming to enhance the oncology portfolio’s clinical development. AstraZeneca plans to leverage AI models for cancer research and development capabilities.

AstraZeneca PLC (NASDAQ:AZN) is a science-led biopharmaceutical company focusing on research, development, and commercialization of prescription medicines in various disease areas. While AZN is considered a strong investment, some AI stocks offer greater upside potential. Explore opportunities in the AI sector for potential growth and benefits from current market trends.

Read more at Yahoo Finance: AstraZeneca PLC (AZN) Partners Modella AI for AI Drug Development